se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19

Not Applicable

Withdrawn

• Conditions: COVID-19; Infection - Other infectious diseases; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620000447954
• Lead Sponsor: Royal Brisbane & Women's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-06
• Last Update Posted: 16 March 2021

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Patients admitted to ICU at the Royal Brisbane & Women's Hospital with suspected or proven severe COVID-19 infection, prescribed hydroxychloroquine as part of their routine management.

Exclusion Criteria

Individuals aged <18 years old.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)<br><br>Dose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]